|
|||||
|
|
A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor,in healthy subjects: reply |
|
| Authors: | J. Zhou N. Miyoshi |
| Affiliation: | 1. Cardiovascular and Metabolic Disease Clinical Development, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA;2. End‐Organ Disease Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan |
| Abstract: | |
| Keywords: | |